Paris, September 13, 2022 – 5:45 p.m. – Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO), a company specializing in the early and precise detection of cancer with a unique and fully automated solution for medical diagnostic laboratories, announces its first partnership for the sale of the Ikoniscope20 digital fluorescence microscope solution in the Eastern European market.
As announced during Ikonisys’ IPO, the go-to-market strategy will focus on a mix model of direct and indirect sales. The direct marketing strategy relies on Ikonisys’ own sales force in the United States and major European countries, while the indirect channel relies on partnerships with qualified distributors with a strong presence in the field of molecular pathologies in their respective markets. The collaboration with BioVendor will initially focus on their partner market, the Czech Republic and Slovakia, with the possibility of extending the collaboration to Austria and the United Kingdom thereafter.